权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

New system of central diagnoses of acute myeloid leukemia in the multi-institutional cooperative study.

多机构合作研究急性髓系白血病中心诊断新系统

基本信息

批准号：
15590492
负责人：
KURIYAMA Kazutaka
金额：
$ 2.18万
依托单位：
University of the Ryukyus (2005)Nagasaki University (2003-2004)
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

项目摘要

Purpose : Treatment strategy for acute myeloid leukemia (AML) is now adding individual therapy based on molecular targeting. To meet that, the system of diagnosing AML in the Japan Adult Leukemia Study Group (JALSG) needs to be changed to the World Health Organization (WHO) classification, which includes several subtypes with specific genetic abnormalities, from the French-American-British (FAB) classification, which is mainly based on morphological findings.In this research project we investigate if the new diagnostic system works well and establish AML subtypes in Japan according to the WHO classification. We also take morphological pictures of individual stained slides using digital camera and report data sheet fulfilled by morphological findings combined with the digital pictures to each institution using the web site of JALSG.Results : We adjusted some conditions of taking pictures using microscopy with digital camera, and established the reporting system of fulfilled data sheet and several morphological pictures using the web site of JALSG. We now try to make data base of AML morphological pictures added to clinical data to study the AML morphology.Of the cases entered the three AML protocols, 1518 cases had data on the chromosomal karyotypes and were diagnosed according to the WHO classification. Three hundred and fifty-five cases (23.4%) were included to the first category of AML/WHO, consisting of 239 cases (15.7%) having t (8;21), 58 cases (3.8%) having inv (16) and 58 cases (3.8%) having 11q23 abnormalities. 372 cases (24.5%) and 791 cases (52.1%) were diagnosed AML with multilineage dysplasia and AML not otherwise categorized, respectively.

目的：急性髓系白血病(AML)的治疗策略是在分子靶向基础上增加个体化治疗。为了满足这一要求，日本成人白血病研究小组(JALSG)的AML诊断系统需要从主要基于形态学发现的法国-美国-英国(FAB)分类改为世界卫生组织(WHO)分类，其中包括几个具有特定遗传异常的亚型。在本研究项目中，我们调查新的诊断系统是否有效，并根据WHO的分类在日本建立AML亚型。用数码相机拍摄单个染色切片的形态图片，并利用JALSG的网站向各机构提交由形态发现结合数码图片填写的数据表。结果：调整了数码相机显微镜拍照的一些条件，建立了利用JALSG网站填写的数据单和多张形态图片的报告系统。现将AML形态图片库与临床资料相结合，建立AML形态图片库，对AML形态进行研究，其中1518例患者有染色体核型资料，按WHO分类诊断。355例(23.4%)纳入第一类AML/WHO，其中t(8；21)239例(15.7%)，inv(16)58例(3.8%)，11q23异常58例(3.8%)。372例(24.5%)AML合并多系异型增生，791例(52.1%)AML未分类。